ArticleBMC medical imaging2025
Gd-EOB-DTPA-enhanced hepatobiliary phase MRI characteristics of inflammatory hepatic adenoma.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the imaging characteristics of the hepatocyte-specific contrast agent gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) in inflammatory hepatocellular adenoma.
methodsThe clinical data and magnetic resonance imaging (MRI) manifestations of 13 patients with pathologically confirmed I-HCA were retrospectively analyzed. There were 10 males and 3 females with an average age of 33.1 ± 10.7years. All patients underwent enhanced MR examination with Gd-EOB-DTPA (a hepatocyte-specific contrast agent). Image analysis included the number, location, size, morphology, plain scan signal, enhancement characteristics, and hepatobiliary-specific phase (HBP). The apparent diffusion coefficient (ADC) values of the lesions and surrounding normal liver parenchyma were measured on the ADC map, and the difference was compared by paired sample t-test.
resultsIn this study, CRP showed a high rate of positive results; there was positive reactivity for CD34 in all patients. Among the 13 cases, 8 cases were single and 5 were multiple, for a total of 26 lesions. The margins of the lesions were all clear, and mostly round or oval; T1WI showed equal or high signal, T2WI showed high signal, DWI showed high signal, the arterial phase was highly enhanced, and the portal phase was not clear. 21 lesions in the hepatobiliary-specific phase had no uptake. The atoll sign was present in only 12% of cases. There was no significant difference between the average ADC value of the lesion and the average ADC value of the adjacent normal liver parenchyma (P = 0.620). The study revealed positive reactivity for C-reactive protein (CRP) and CD34.
conclusionThe Gd-EOB-DTPA-enhanced hepatobiliary phase MRI of I-HCA exhibits certain characteristic features, which serve as an aid in the diagnosis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.